COVID-19 UPDATE

BDSI remains committed to the chronic pain community during the COVID-19 pandemic. For more
information on access to our products, please call our customer service line at 1-800-469-0261.

NEWS: BDSI Completes Acquisition of ELYXYB™ Learn More >
NEWS: BDSI Completes Acquisition of ELYXYB™ Learn More >
BDSI
BDSI
INSPIRING SOLUTIONS FOR BETTER HEALTH
BDSI advances novel therapies designed to improve the lives of people living with serious and debilitating chronic conditions
Thomas Smith, MD, Chief Medical Officer at BDSI, interviews healthcare experts on what patients living with chronic pain experience.

Listening to healthcare practitioners helps us understand how we can deliver meaningful solutions to the patient community. We are dedicated to the constant pursuit of improving patients’ lives.

Watch now

Purpose

BioDelivery Sciences International (BDSI) is a rapidly growing specialty pharmaceutical company working to deliver innovative therapies for individuals living with serious and debilitating chronic conditions.

Learn more

Patients

BDSI subscribes to a patients-first philosophy. We are a dynamic team driven by the knowledge that the work we do can have a positive impact on patients, their caretakers, and loved ones.

Learn more

Products

BDSI offers a diverse portfolio of solutions for the treatment of serious and debilitating chronic conditions, including unique therapeutic innovations like a buccal film technology designed to help optimize drug delivery.

Learn more

Recent BDSI News

September 30, 2021

The First and Only FDA-Approved, Ready-to-Use Oral Solution for the Acute Treatment of Migraine with or without Aura in Adults Virtual Event on October 14, 2021 RALEIGH, N.C. , Sept. 30, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International , Inc. (NASDAQ: BDSI), a growing specialty

Read more
September 9, 2021

Expands Portfolio and Establishes Growth Platform in Neurology The First and Only FDA-Approved, Ready-to-Use Oral Solution for the Acute Treatment of Migraine with or without Aura in Adults Commercial Launch Planned for Q1 2022 Investor Day on October 14, 2021 RALEIGH, N.C. , Sept.

Read more
September 7, 2021

RALEIGH, N.C. , Sept. 07, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International , Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with chronic conditions, will showcase three scientific posters regarding BELBUCA ®  (buprenorphine buccal film), CIII

Read more
More news

Upcoming Events

There are no events to display

Stay Connected

Stay up to date on the latest news

Get started now
October 18, 2021BDSI $4.08/ - 1.75%
Data provided by Nasdaq. Minimum 15 minutes delayed.